



Sweden

(12) Patent specification

(10) SE 539 450 C2

(21) Patent application number:	1650260-1	(51) Int.Cl.:
(45) Grant of patent:	2017-09-26	<b>A61K 31/506</b> (2006.01)
(41) Available to the public:	2017-08-30	<b>A61P 9/00</b> (2006.01)
(22) Filing date:	2016-02-29	
(24) Effective date:	2016-02-29	
(30) Priority data:	---	

(73) Patentee: Hamra Invest AB, Hägervägen 27, 746 34 Bålsta SE  
Brain consultant Nils Gunnar Wahlgren AB, Sagostigen 8, 167 54 Bromma SE  
(72) Inventor: Ulf Eriksson, Bålsta SE  
Nils Gunnar Wahlgren, Bromma SE  
(74) Agent: KRANSELL & WENNBORG KB, Box 27834, 115 93, Stockholm SE  
(54) Title: Imatinib for use in the treatment of stroke  
(56) Cited documents: WO 2006121941 A2 · US 20090264438 A1  
(57) Abstract:

Imatinib can be used in the treatment of stroke in a new dosage regime, where Imatinib is administered to the patient at a dose of 650 mg/day or higher for at least 3 consecutive days, and preferably administered in a starting dose of 1000 mg/day or higher on day 1, and at a dose in the interval of 650 mg/day to 1000 mg/day on the subsequent days. A method for the treatment of stroke, a pharmaceutical composition and a kit of parts is/are also disclosed.